<?xml version="1.0" encoding="utf-8"?>
<Label drug="BRILINTA" setid="f7b3f443-e83d-4bf2-0e96-023448fed9a8">
<Text><Section name="Boxed Warning section" id="34066-1">
WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS 

 A. BLEEDING RISK 


 BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). 


 Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage ( 4.1 , 4.2 ). 


 Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , 6.1 ). 


 If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events 

 (5.4) 

 . 

 B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS 


 Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided ( 2.1 , 5.2 , 

 14.1 

 ). 

 WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS 

 See full prescribing information for complete boxed warning. 

 BLEEDING RISK 

 
 BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). 

 
 Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage ( 4.1 , 4.2 ). 

 
 Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , 6.1 ). 

 
 If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events 

 (5.4) 

 . 

 ASPIRIN DOSE AND BRILINTA EFFECTIVENESS 

 
 Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. ( 2.1 , 5.2 , 

 14.1 

 ).</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION 

 Initiate treatment with 180 mg oral loading dose following an ACS event. Continue treatment with 90 mg twice daily during the first year after an ACS event. After one year, administer 60 mg twice daily. (2.1) 

 Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg. ( 2.1 , 5.2 ) 

 2.1 Dosing 

 In the management of ACS, initiate BRILINTA treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. 
 Do not administer BRILINTA with another oral P2Y 12 platelet inhibitor. 
 Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg [ see 

 Warnings and Precautions (5.2) 

 and 

 Clinical Studies (14.1) 
 ]. A patient who misses a dose of BRILINTA should take one tablet (their next dose) at its scheduled time. 

 2.2 Administration 

 For patients who are unable to swallow tablets whole, BRILINTA tablets can be crushed, mixed with water and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater) [ see 

 Clinical Pharmacology (12.3) 
 ].</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS 

 History of intracranial hemorrhage. (4.1) 

 Active pathological bleeding. (4.2) 

 Hypersensitivity to ticagrelor or any component of the product. (4.3) 

 4.1 History of Intracranial Hemorrhage 

 BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [ see 

 Clinical Studies (14.1) 
 ] . 

 4.2 Active Bleeding 

 BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [ see Warnings and Precautions (5.1) and Adverse Reactions (6.1) 
 ]. 

 4.3 Hypersensitivity 

 BRILINTA is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product.</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 Dyspnea was reported more frequently with BRILINTA than with control agents in clinical trials. Dyspnea resulting from BRILINTA is self-limiting. (5.3) 

 Severe Hepatic Impairment: Likely increase in exposure to ticagrelor. (5.6) 

 5.1 General Risk of Bleeding 

 Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding [see 
 Adverse Reactions (6.1) 
 ]. 
 If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events [ see 

 Warnings and Precautions (5.4) 

 and Adverse Reactions (6.1) 
 ]. 

 5.2 Concomitant Aspirin Maintenance Dose 

 In PLATO the use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Therefore, after the initial loading dose of aspirin, use BRILINTA with a maintenance dose of aspirin of 75-100 mg [ see 

 Dosage and Administration (2.1) 

 and 

 Clinical Studies (14.1) 
 ] . 

 5.3 Dyspnea 

 In clinical trials, about 14% of patients treated with BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment, but led to study drug discontinuation in 0.9% of BRILINTA and 0.1% of clopidogrel patients in PLATO and 4.3% of BRILINTA 60 mg and 0.7% on aspirin alone patients in PEGASUS. 
 In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment. 
 If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to BRILINTA, no specific treatment is required; continue BRILINTA without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent. 

 5.4 Discontinuation of BRILINTA 

 Discontinuation of BRILINTA will increase the risk of myocardial infarction, stroke, and death. If BRILINTA must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of bleeding. Resume BRILINTA as soon as hemostasis is achieved. 

 5.5 Bradyarrhythmias 

 Ticagrelor can cause ventricular pauses [ see Adverse Reactions (6.1) 
 ]. Bradyarrhythmias including AV block have been reported in the postmarketing setting. Patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker were excluded from PLATO and PEGASUS and may be at increased risk of developing bradyarrhythmias with ticagrelor. 

 5.6 Severe Hepatic Impairment 

 Avoid use of BRILINTA in patients with severe hepatic impairment. Severe hepatic impairment is likely to increase serum concentration of ticagrelor. There are no studies of BRILINTA patients with severe hepatic impairment [ see Clinical Pharmacology (12.3) 
 ] .</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS 

 Avoid use with strong CYP3A inhibitors or CYP3A inducers. ( 7.1 , 7.2 ) 

 Opioids : Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent. ( 7.4 ) 

 Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. ( 7.5 ) 

 Monitor digoxin levels with initiation of or any change in BRILINTA. ( 7.6 ) 

 7.1 Strong CYP3A Inhibitors 

 Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [ see 

 Clinical Pharmacology (12.3) 
 ]. 

 7.2 Strong CYP3A Inducers 

 Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor. Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [ see 

 Clinical Pharmacology (12.3) 
 ]. 

 7.3 Aspirin 

 Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA [ see Warnings and Precautions (5.2) and 

 Clinical Studies (14.1) 
 ] . 

 7.4 Opioids 

 As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor and its active metabolite presumably because of slowed gastric emptying [ see Clinical Pharmacology (12.3) 
 ]. Consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists. 

 7.5 Simvastatin, Lovastatin 

 BRILINTA increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg [ see Clinical Pharmacology (12.3) 
 ]. 

 7.6 Digoxin 

 BRILINTA inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in BRILINTA therapy [ see Clinical Pharmacology (12.3) 
 ].</Section>
</Text><Sentences>
<Sentence id="523" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .</SentenceText>
</Sentence>
<Sentence id="524" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>BRILINTA , like other antiplatelet agents , can cause significant , sometimes fatal bleeding ( 5.1 , 6.1 ) .</SentenceText>
</Sentence>
<Sentence id="525" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided ( 2.1 , 5.2 , 14.1 ) .</SentenceText>
<Mention id="M1" type="Trigger" span="42 24" str="reduce the effectiveness"/>
<Mention id="M2" type="Precipitant" span="21 7" str="aspirin" code="N0000006582"/>
<Mention id="M3" type="SpecificInteraction" span="42 36" str="reduce the effectiveness of BRILINTA" code="NO MAP"/>
<Interaction id="I1" type="Pharmacodynamic interaction" trigger="M1" precipitant="M2" effect="M3"/>
</Sentence>
<Sentence id="526" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided .</SentenceText>
<Mention id="M4" type="Trigger" span="42 24" str="reduce the effectiveness"/>
<Mention id="M5" type="Precipitant" span="21 7" str="aspirin" code="N0000006582"/>
<Mention id="M6" type="SpecificInteraction" span="42 36" str="reduce the effectiveness of BRILINTA" code="NO MAP"/>
<Interaction id="I2" type="Pharmacodynamic interaction" trigger="M4" precipitant="M5" effect="M6"/>
</Sentence>
<Sentence id="527" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>WARNING : ( A ) BLEEDING RISK , ( B ) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .</SentenceText>
</Sentence>
<Sentence id="528" LabelDrug="BRILINTA" section="34066-1">
<SentenceText>WARNING : ( A ) BLEEDING RISK , and ( B ) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .</SentenceText>
</Sentence>
<Sentence id="529" LabelDrug="BRILINTA" section="34068-7">
<SentenceText>Do not administer BRILINTA with another oral P2Y12 platelet inhibitor .</SentenceText>
<Mention id="M7" type="Trigger" span="0 17" str="Do not administer"/>
<Mention id="M8" type="Precipitant" span="45 24" str="P2Y12 platelet inhibitor" code="N0000182142"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M7" precipitant="M8"/>
</Sentence>
<Sentence id="530" LabelDrug="BRILINTA" section="34068-7">
<SentenceText>Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg .</SentenceText>
</Sentence>
<Sentence id="531" LabelDrug="BRILINTA" section="34068-7">
<SentenceText>Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.1 ) .</SentenceText>
</Sentence>
<Sentence id="532" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>(7.1, 7.2) Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.</SentenceText>
<Mention id="M12" type="Trigger" span="93 14" str="increased risk"/>
<Mention id="M10" type="Precipitant" span="72 10" str="lovastatin" code="N0000007106"/>
<Mention id="M14" type="SpecificInteraction" span="111 30" str="statin-related adverse effects" code="NO MAP"/>
<Mention id="M13" type="Precipitant" span="57 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I4" type="Pharmacodynamic interaction" trigger="M12" precipitant="M10" effect="M14"/>
<Interaction id="I5" type="Pharmacodynamic interaction" trigger="M12" precipitant="M13" effect="M14"/>
</Sentence>
<Sentence id="532" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>(7.1, 7.2) Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.</SentenceText>
<Mention id="M18" type="Trigger" span="93 14" str="increased risk"/>
<Mention id="M16" type="Precipitant" span="72 10" str="lovastatin" code="N0000007106"/>
<Mention id="M20" type="SpecificInteraction" span="111 30" str="statin-related adverse effects" code="NO MAP"/>
<Mention id="M19" type="Precipitant" span="57 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I6" type="Pharmacodynamic interaction" trigger="M18" precipitant="M16" effect="M20"/>
<Interaction id="I7" type="Pharmacodynamic interaction" trigger="M18" precipitant="M19" effect="M20"/>
</Sentence>
<Sentence id="533" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>(7.4) Monitor digoxin levels with initiation of or any change in BRILINTA.</SentenceText>
<Mention id="M21" type="Trigger" span="6 7" str="Monitor"/>
<Mention id="M22" type="Precipitant" span="14 7" str="digoxin" code="N0000005903"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M21" precipitant="M22"/>
</Sentence>
<Sentence id="534" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>(7.5) Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events.</SentenceText>
<Mention id="M23" type="Trigger" span="80 17" str="increase the risk"/>
<Mention id="M28" type="Precipitant" span="13 16" str="CYP3A inhibitors" code="N0000191001"/>
<Mention id="M25" type="SpecificInteraction" span="101 7" str="dyspnea " code="267036007: Dyspnea (finding)"/>
<Mention id="M26" type="SpecificInteraction" span="110 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Mention id="M27" type="Trigger" span="44 8;64 8" str="increase | exposure"/>
<Interaction id="I9" type="Pharmacodynamic interaction" trigger="M23" precipitant="M28" effect="M25;M26"/>
<Interaction id="I10" type="Pharmacokinetic interaction" trigger="M27" precipitant="M28" effect="C54355"/>
</Sentence>
<Sentence id="534" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>(7.5) Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events.</SentenceText>
<Mention id="M29" type="Trigger" span="80 17" str="increase the risk"/>
<Mention id="M34" type="Precipitant" span="13 16" str="CYP3A inhibitors" code="N0000191001"/>
<Mention id="M31" type="SpecificInteraction" span="101 7" str="dyspnea " code="267036007: Dyspnea (finding)"/>
<Mention id="M32" type="SpecificInteraction" span="110 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Mention id="M33" type="Trigger" span="44 8;64 8" str="increase | exposure"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M29" precipitant="M34" effect="M31;M32"/>
<Interaction id="I12" type="Pharmacokinetic interaction" trigger="M33" precipitant="M34" effect="C54355"/>
</Sentence>
<Sentence id="535" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M37" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M36" type="Precipitant" span="22 10" str="lovastatin" code="N0000007106"/>
<Mention id="M38" type="Precipitant" span="6 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I13" type="Unspecified interaction" trigger="M37" precipitant="M36"/>
<Interaction id="I14" type="Unspecified interaction" trigger="M37" precipitant="M38"/>
</Sentence>
<Sentence id="535" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M41" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M40" type="Precipitant" span="22 10" str="lovastatin" code="N0000007106"/>
<Mention id="M42" type="Precipitant" span="6 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I15" type="Unspecified interaction" trigger="M41" precipitant="M40"/>
<Interaction id="I16" type="Unspecified interaction" trigger="M41" precipitant="M42"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M65" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M44" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M46" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M48" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M50" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M52" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M54" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M56" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M58" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M60" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M62" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M64" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M66" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I17" type="Unspecified interaction" trigger="M65" precipitant="M44"/>
<Interaction id="I18" type="Unspecified interaction" trigger="M65" precipitant="M46"/>
<Interaction id="I19" type="Unspecified interaction" trigger="M65" precipitant="M48"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M65" precipitant="M50"/>
<Interaction id="I21" type="Unspecified interaction" trigger="M65" precipitant="M52"/>
<Interaction id="I22" type="Unspecified interaction" trigger="M65" precipitant="M54"/>
<Interaction id="I23" type="Unspecified interaction" trigger="M65" precipitant="M56"/>
<Interaction id="I24" type="Unspecified interaction" trigger="M65" precipitant="M58"/>
<Interaction id="I25" type="Unspecified interaction" trigger="M65" precipitant="M60"/>
<Interaction id="I26" type="Unspecified interaction" trigger="M65" precipitant="M62"/>
<Interaction id="I27" type="Unspecified interaction" trigger="M65" precipitant="M64"/>
<Interaction id="I28" type="Unspecified interaction" trigger="M65" precipitant="M66"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M89" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M68" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M70" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M72" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M74" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M76" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M78" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M80" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M82" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M84" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M86" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M88" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M90" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I29" type="Unspecified interaction" trigger="M89" precipitant="M68"/>
<Interaction id="I30" type="Unspecified interaction" trigger="M89" precipitant="M70"/>
<Interaction id="I31" type="Unspecified interaction" trigger="M89" precipitant="M72"/>
<Interaction id="I32" type="Unspecified interaction" trigger="M89" precipitant="M74"/>
<Interaction id="I33" type="Unspecified interaction" trigger="M89" precipitant="M76"/>
<Interaction id="I34" type="Unspecified interaction" trigger="M89" precipitant="M78"/>
<Interaction id="I35" type="Unspecified interaction" trigger="M89" precipitant="M80"/>
<Interaction id="I36" type="Unspecified interaction" trigger="M89" precipitant="M82"/>
<Interaction id="I37" type="Unspecified interaction" trigger="M89" precipitant="M84"/>
<Interaction id="I38" type="Unspecified interaction" trigger="M89" precipitant="M86"/>
<Interaction id="I39" type="Unspecified interaction" trigger="M89" precipitant="M88"/>
<Interaction id="I40" type="Unspecified interaction" trigger="M89" precipitant="M90"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M113" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M92" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M94" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M96" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M98" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M100" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M102" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M104" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M106" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M108" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M110" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M112" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M114" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I41" type="Unspecified interaction" trigger="M113" precipitant="M92"/>
<Interaction id="I42" type="Unspecified interaction" trigger="M113" precipitant="M94"/>
<Interaction id="I43" type="Unspecified interaction" trigger="M113" precipitant="M96"/>
<Interaction id="I44" type="Unspecified interaction" trigger="M113" precipitant="M98"/>
<Interaction id="I45" type="Unspecified interaction" trigger="M113" precipitant="M100"/>
<Interaction id="I46" type="Unspecified interaction" trigger="M113" precipitant="M102"/>
<Interaction id="I47" type="Unspecified interaction" trigger="M113" precipitant="M104"/>
<Interaction id="I48" type="Unspecified interaction" trigger="M113" precipitant="M106"/>
<Interaction id="I49" type="Unspecified interaction" trigger="M113" precipitant="M108"/>
<Interaction id="I50" type="Unspecified interaction" trigger="M113" precipitant="M110"/>
<Interaction id="I51" type="Unspecified interaction" trigger="M113" precipitant="M112"/>
<Interaction id="I52" type="Unspecified interaction" trigger="M113" precipitant="M114"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M137" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M116" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M118" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M120" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M122" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M124" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M126" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M128" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M130" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M132" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M134" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M136" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M138" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I53" type="Unspecified interaction" trigger="M137" precipitant="M116"/>
<Interaction id="I54" type="Unspecified interaction" trigger="M137" precipitant="M118"/>
<Interaction id="I55" type="Unspecified interaction" trigger="M137" precipitant="M120"/>
<Interaction id="I56" type="Unspecified interaction" trigger="M137" precipitant="M122"/>
<Interaction id="I57" type="Unspecified interaction" trigger="M137" precipitant="M124"/>
<Interaction id="I58" type="Unspecified interaction" trigger="M137" precipitant="M126"/>
<Interaction id="I59" type="Unspecified interaction" trigger="M137" precipitant="M128"/>
<Interaction id="I60" type="Unspecified interaction" trigger="M137" precipitant="M130"/>
<Interaction id="I61" type="Unspecified interaction" trigger="M137" precipitant="M132"/>
<Interaction id="I62" type="Unspecified interaction" trigger="M137" precipitant="M134"/>
<Interaction id="I63" type="Unspecified interaction" trigger="M137" precipitant="M136"/>
<Interaction id="I64" type="Unspecified interaction" trigger="M137" precipitant="M138"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M161" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M140" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M142" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M144" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M146" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M148" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M150" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M152" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M154" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M156" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M158" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M160" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M162" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I65" type="Unspecified interaction" trigger="M161" precipitant="M140"/>
<Interaction id="I66" type="Unspecified interaction" trigger="M161" precipitant="M142"/>
<Interaction id="I67" type="Unspecified interaction" trigger="M161" precipitant="M144"/>
<Interaction id="I68" type="Unspecified interaction" trigger="M161" precipitant="M146"/>
<Interaction id="I69" type="Unspecified interaction" trigger="M161" precipitant="M148"/>
<Interaction id="I70" type="Unspecified interaction" trigger="M161" precipitant="M150"/>
<Interaction id="I71" type="Unspecified interaction" trigger="M161" precipitant="M152"/>
<Interaction id="I72" type="Unspecified interaction" trigger="M161" precipitant="M154"/>
<Interaction id="I73" type="Unspecified interaction" trigger="M161" precipitant="M156"/>
<Interaction id="I74" type="Unspecified interaction" trigger="M161" precipitant="M158"/>
<Interaction id="I75" type="Unspecified interaction" trigger="M161" precipitant="M160"/>
<Interaction id="I76" type="Unspecified interaction" trigger="M161" precipitant="M162"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M185" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M164" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M166" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M168" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M170" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M172" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M174" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M176" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M178" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M180" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M182" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M184" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M186" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I77" type="Unspecified interaction" trigger="M185" precipitant="M164"/>
<Interaction id="I78" type="Unspecified interaction" trigger="M185" precipitant="M166"/>
<Interaction id="I79" type="Unspecified interaction" trigger="M185" precipitant="M168"/>
<Interaction id="I80" type="Unspecified interaction" trigger="M185" precipitant="M170"/>
<Interaction id="I81" type="Unspecified interaction" trigger="M185" precipitant="M172"/>
<Interaction id="I82" type="Unspecified interaction" trigger="M185" precipitant="M174"/>
<Interaction id="I83" type="Unspecified interaction" trigger="M185" precipitant="M176"/>
<Interaction id="I84" type="Unspecified interaction" trigger="M185" precipitant="M178"/>
<Interaction id="I85" type="Unspecified interaction" trigger="M185" precipitant="M180"/>
<Interaction id="I86" type="Unspecified interaction" trigger="M185" precipitant="M182"/>
<Interaction id="I87" type="Unspecified interaction" trigger="M185" precipitant="M184"/>
<Interaction id="I88" type="Unspecified interaction" trigger="M185" precipitant="M186"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M209" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M188" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M190" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M192" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M194" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M196" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M198" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M200" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M202" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M204" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M206" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M208" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M210" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I89" type="Unspecified interaction" trigger="M209" precipitant="M188"/>
<Interaction id="I90" type="Unspecified interaction" trigger="M209" precipitant="M190"/>
<Interaction id="I91" type="Unspecified interaction" trigger="M209" precipitant="M192"/>
<Interaction id="I92" type="Unspecified interaction" trigger="M209" precipitant="M194"/>
<Interaction id="I93" type="Unspecified interaction" trigger="M209" precipitant="M196"/>
<Interaction id="I94" type="Unspecified interaction" trigger="M209" precipitant="M198"/>
<Interaction id="I95" type="Unspecified interaction" trigger="M209" precipitant="M200"/>
<Interaction id="I96" type="Unspecified interaction" trigger="M209" precipitant="M202"/>
<Interaction id="I97" type="Unspecified interaction" trigger="M209" precipitant="M204"/>
<Interaction id="I98" type="Unspecified interaction" trigger="M209" precipitant="M206"/>
<Interaction id="I99" type="Unspecified interaction" trigger="M209" precipitant="M208"/>
<Interaction id="I100" type="Unspecified interaction" trigger="M209" precipitant="M210"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M233" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M212" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M214" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M216" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M218" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M220" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M222" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M224" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M226" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M228" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M230" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M232" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M234" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I101" type="Unspecified interaction" trigger="M233" precipitant="M212"/>
<Interaction id="I102" type="Unspecified interaction" trigger="M233" precipitant="M214"/>
<Interaction id="I103" type="Unspecified interaction" trigger="M233" precipitant="M216"/>
<Interaction id="I104" type="Unspecified interaction" trigger="M233" precipitant="M218"/>
<Interaction id="I105" type="Unspecified interaction" trigger="M233" precipitant="M220"/>
<Interaction id="I106" type="Unspecified interaction" trigger="M233" precipitant="M222"/>
<Interaction id="I107" type="Unspecified interaction" trigger="M233" precipitant="M224"/>
<Interaction id="I108" type="Unspecified interaction" trigger="M233" precipitant="M226"/>
<Interaction id="I109" type="Unspecified interaction" trigger="M233" precipitant="M228"/>
<Interaction id="I110" type="Unspecified interaction" trigger="M233" precipitant="M230"/>
<Interaction id="I111" type="Unspecified interaction" trigger="M233" precipitant="M232"/>
<Interaction id="I112" type="Unspecified interaction" trigger="M233" precipitant="M234"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M257" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M236" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M238" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M240" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M242" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M244" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M246" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M248" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M250" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M252" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M254" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M256" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M258" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I113" type="Unspecified interaction" trigger="M257" precipitant="M236"/>
<Interaction id="I114" type="Unspecified interaction" trigger="M257" precipitant="M238"/>
<Interaction id="I115" type="Unspecified interaction" trigger="M257" precipitant="M240"/>
<Interaction id="I116" type="Unspecified interaction" trigger="M257" precipitant="M242"/>
<Interaction id="I117" type="Unspecified interaction" trigger="M257" precipitant="M244"/>
<Interaction id="I118" type="Unspecified interaction" trigger="M257" precipitant="M246"/>
<Interaction id="I119" type="Unspecified interaction" trigger="M257" precipitant="M248"/>
<Interaction id="I120" type="Unspecified interaction" trigger="M257" precipitant="M250"/>
<Interaction id="I121" type="Unspecified interaction" trigger="M257" precipitant="M252"/>
<Interaction id="I122" type="Unspecified interaction" trigger="M257" precipitant="M254"/>
<Interaction id="I123" type="Unspecified interaction" trigger="M257" precipitant="M256"/>
<Interaction id="I124" type="Unspecified interaction" trigger="M257" precipitant="M258"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M281" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M260" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M262" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M264" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M266" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M268" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M270" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M272" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M274" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M276" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M278" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M280" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M282" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I125" type="Unspecified interaction" trigger="M281" precipitant="M260"/>
<Interaction id="I126" type="Unspecified interaction" trigger="M281" precipitant="M262"/>
<Interaction id="I127" type="Unspecified interaction" trigger="M281" precipitant="M264"/>
<Interaction id="I128" type="Unspecified interaction" trigger="M281" precipitant="M266"/>
<Interaction id="I129" type="Unspecified interaction" trigger="M281" precipitant="M268"/>
<Interaction id="I130" type="Unspecified interaction" trigger="M281" precipitant="M270"/>
<Interaction id="I131" type="Unspecified interaction" trigger="M281" precipitant="M272"/>
<Interaction id="I132" type="Unspecified interaction" trigger="M281" precipitant="M274"/>
<Interaction id="I133" type="Unspecified interaction" trigger="M281" precipitant="M276"/>
<Interaction id="I134" type="Unspecified interaction" trigger="M281" precipitant="M278"/>
<Interaction id="I135" type="Unspecified interaction" trigger="M281" precipitant="M280"/>
<Interaction id="I136" type="Unspecified interaction" trigger="M281" precipitant="M282"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M305" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M284" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M286" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M288" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M290" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M292" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M294" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M296" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M298" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M300" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M302" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M304" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M306" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I137" type="Unspecified interaction" trigger="M305" precipitant="M284"/>
<Interaction id="I138" type="Unspecified interaction" trigger="M305" precipitant="M286"/>
<Interaction id="I139" type="Unspecified interaction" trigger="M305" precipitant="M288"/>
<Interaction id="I140" type="Unspecified interaction" trigger="M305" precipitant="M290"/>
<Interaction id="I141" type="Unspecified interaction" trigger="M305" precipitant="M292"/>
<Interaction id="I142" type="Unspecified interaction" trigger="M305" precipitant="M294"/>
<Interaction id="I143" type="Unspecified interaction" trigger="M305" precipitant="M296"/>
<Interaction id="I144" type="Unspecified interaction" trigger="M305" precipitant="M298"/>
<Interaction id="I145" type="Unspecified interaction" trigger="M305" precipitant="M300"/>
<Interaction id="I146" type="Unspecified interaction" trigger="M305" precipitant="M302"/>
<Interaction id="I147" type="Unspecified interaction" trigger="M305" precipitant="M304"/>
<Interaction id="I148" type="Unspecified interaction" trigger="M305" precipitant="M306"/>
</Sentence>
<Sentence id="536" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M329" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M308" type="Precipitant" span="163 10" str="atazanavir" code="N0000022320"/>
<Mention id="M310" type="Precipitant" span="89 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M312" type="Precipitant" span="152 9" str="indinavir" code="N0000005722"/>
<Mention id="M314" type="Precipitant" span="20 19" str="inhibitors of CYP3A" code="N0000191001"/>
<Mention id="M316" type="Precipitant" span="61 12" str="itraconazole" code="N0000006753"/>
<Mention id="M318" type="Precipitant" span="47 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M320" type="Precipitant" span="105 10" str="nefazodone" code="N0000007250"/>
<Mention id="M322" type="Precipitant" span="140 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M324" type="Precipitant" span="117 9" str="ritonavir" code="N0000007423"/>
<Mention id="M326" type="Precipitant" span="128 10" str="saquinavir" code="N0000007376"/>
<Mention id="M328" type="Precipitant" span="178 13" str="telithromycin" code="N0000010551"/>
<Mention id="M330" type="Precipitant" span="75 12" str="voriconazole" code="N0000010191"/>
<Interaction id="I149" type="Unspecified interaction" trigger="M329" precipitant="M308"/>
<Interaction id="I150" type="Unspecified interaction" trigger="M329" precipitant="M310"/>
<Interaction id="I151" type="Unspecified interaction" trigger="M329" precipitant="M312"/>
<Interaction id="I152" type="Unspecified interaction" trigger="M329" precipitant="M314"/>
<Interaction id="I153" type="Unspecified interaction" trigger="M329" precipitant="M316"/>
<Interaction id="I154" type="Unspecified interaction" trigger="M329" precipitant="M318"/>
<Interaction id="I155" type="Unspecified interaction" trigger="M329" precipitant="M320"/>
<Interaction id="I156" type="Unspecified interaction" trigger="M329" precipitant="M322"/>
<Interaction id="I157" type="Unspecified interaction" trigger="M329" precipitant="M324"/>
<Interaction id="I158" type="Unspecified interaction" trigger="M329" precipitant="M326"/>
<Interaction id="I159" type="Unspecified interaction" trigger="M329" precipitant="M328"/>
<Interaction id="I160" type="Unspecified interaction" trigger="M329" precipitant="M330"/>
</Sentence>
<Sentence id="537" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong CYP3A inhibitors or CYP3A inducers.</SentenceText>
<Mention id="M333" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M332" type="Precipitant" span="42 14" str="CYP3A inducers" code="n0000190118"/>
<Mention id="M334" type="Precipitant" span="22 16" str="CYP3A inhibitors" code="N0000191001"/>
<Interaction id="I161" type="Unspecified interaction" trigger="M333" precipitant="M332"/>
<Interaction id="I162" type="Unspecified interaction" trigger="M333" precipitant="M334"/>
</Sentence>
<Sentence id="537" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong CYP3A inhibitors or CYP3A inducers.</SentenceText>
<Mention id="M337" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M336" type="Precipitant" span="42 14" str="CYP3A inducers" code="n0000190118"/>
<Mention id="M338" type="Precipitant" span="22 16" str="CYP3A inhibitors" code="N0000191001"/>
<Interaction id="I163" type="Unspecified interaction" trigger="M337" precipitant="M336"/>
<Interaction id="I164" type="Unspecified interaction" trigger="M337" precipitant="M338"/>
</Sentence>
<Sentence id="538" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M347" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M340" type="Precipitant" span="68 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M342" type="Precipitant" span="22 17" str="inducers of CYP3A" code="n0000190118"/>
<Mention id="M344" type="Precipitant" span="86 13" str="phenobarbital" code="N0000005893"/>
<Mention id="M346" type="Precipitant" span="57 9" str="phenytoin" code="N0000006023"/>
<Mention id="M348" type="Precipitant" span="47 8" str="rifampin" code="N0000006026"/>
<Interaction id="I165" type="Unspecified interaction" trigger="M347" precipitant="M340"/>
<Interaction id="I166" type="Unspecified interaction" trigger="M347" precipitant="M342"/>
<Interaction id="I167" type="Unspecified interaction" trigger="M347" precipitant="M344"/>
<Interaction id="I168" type="Unspecified interaction" trigger="M347" precipitant="M346"/>
<Interaction id="I169" type="Unspecified interaction" trigger="M347" precipitant="M348"/>
</Sentence>
<Sentence id="538" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M357" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M350" type="Precipitant" span="68 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M352" type="Precipitant" span="22 17" str="inducers of CYP3A" code="n0000190118"/>
<Mention id="M354" type="Precipitant" span="86 13" str="phenobarbital" code="N0000005893"/>
<Mention id="M356" type="Precipitant" span="57 9" str="phenytoin" code="N0000006023"/>
<Mention id="M358" type="Precipitant" span="47 8" str="rifampin" code="N0000006026"/>
<Interaction id="I170" type="Unspecified interaction" trigger="M357" precipitant="M350"/>
<Interaction id="I171" type="Unspecified interaction" trigger="M357" precipitant="M352"/>
<Interaction id="I172" type="Unspecified interaction" trigger="M357" precipitant="M354"/>
<Interaction id="I173" type="Unspecified interaction" trigger="M357" precipitant="M356"/>
<Interaction id="I174" type="Unspecified interaction" trigger="M357" precipitant="M358"/>
</Sentence>
<Sentence id="538" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M367" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M360" type="Precipitant" span="68 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M362" type="Precipitant" span="22 17" str="inducers of CYP3A" code="n0000190118"/>
<Mention id="M364" type="Precipitant" span="86 13" str="phenobarbital" code="N0000005893"/>
<Mention id="M366" type="Precipitant" span="57 9" str="phenytoin" code="N0000006023"/>
<Mention id="M368" type="Precipitant" span="47 8" str="rifampin" code="N0000006026"/>
<Interaction id="I175" type="Unspecified interaction" trigger="M367" precipitant="M360"/>
<Interaction id="I176" type="Unspecified interaction" trigger="M367" precipitant="M362"/>
<Interaction id="I177" type="Unspecified interaction" trigger="M367" precipitant="M364"/>
<Interaction id="I178" type="Unspecified interaction" trigger="M367" precipitant="M366"/>
<Interaction id="I179" type="Unspecified interaction" trigger="M367" precipitant="M368"/>
</Sentence>
<Sentence id="538" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M377" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M370" type="Precipitant" span="68 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M372" type="Precipitant" span="22 17" str="inducers of CYP3A" code="n0000190118"/>
<Mention id="M374" type="Precipitant" span="86 13" str="phenobarbital" code="N0000005893"/>
<Mention id="M376" type="Precipitant" span="57 9" str="phenytoin" code="N0000006023"/>
<Mention id="M378" type="Precipitant" span="47 8" str="rifampin" code="N0000006026"/>
<Interaction id="I180" type="Unspecified interaction" trigger="M377" precipitant="M370"/>
<Interaction id="I181" type="Unspecified interaction" trigger="M377" precipitant="M372"/>
<Interaction id="I182" type="Unspecified interaction" trigger="M377" precipitant="M374"/>
<Interaction id="I183" type="Unspecified interaction" trigger="M377" precipitant="M376"/>
<Interaction id="I184" type="Unspecified interaction" trigger="M377" precipitant="M378"/>
</Sentence>
<Sentence id="538" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M387" type="Trigger" span="0 9" str="Avoid use"/>
<Mention id="M380" type="Precipitant" span="68 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M382" type="Precipitant" span="22 17" str="inducers of CYP3A" code="n0000190118"/>
<Mention id="M384" type="Precipitant" span="86 13" str="phenobarbital" code="N0000005893"/>
<Mention id="M386" type="Precipitant" span="57 9" str="phenytoin" code="N0000006023"/>
<Mention id="M388" type="Precipitant" span="47 8" str="rifampin" code="N0000006026"/>
<Interaction id="I185" type="Unspecified interaction" trigger="M387" precipitant="M380"/>
<Interaction id="I186" type="Unspecified interaction" trigger="M387" precipitant="M382"/>
<Interaction id="I187" type="Unspecified interaction" trigger="M387" precipitant="M384"/>
<Interaction id="I188" type="Unspecified interaction" trigger="M387" precipitant="M386"/>
<Interaction id="I189" type="Unspecified interaction" trigger="M387" precipitant="M388"/>
</Sentence>
<Sentence id="539" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>BRILINTA increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4 .</SentenceText>
<Mention id="M391" type="Trigger" span="9 30" str="increases serum concentrations"/>
<Mention id="M390" type="Precipitant" span="59 10" str="lovastatin" code="N0000007106"/>
<Mention id="M392" type="Precipitant" span="43 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I190" type="Pharmacokinetic interaction" trigger="M391" precipitant="M390" effect="C54357"/>
<Interaction id="I191" type="Pharmacokinetic interaction" trigger="M391" precipitant="M392" effect="C54357"/>
</Sentence>
<Sentence id="539" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>BRILINTA increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4 .</SentenceText>
<Mention id="M395" type="Trigger" span="9 30" str="increases serum concentrations"/>
<Mention id="M394" type="Precipitant" span="59 10" str="lovastatin" code="N0000007106"/>
<Mention id="M396" type="Precipitant" span="43 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I192" type="Pharmacokinetic interaction" trigger="M395" precipitant="M394" effect="C54357"/>
<Interaction id="I193" type="Pharmacokinetic interaction" trigger="M395" precipitant="M396" effect="C54357"/>
</Sentence>
<Sentence id="540" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>BRILINTA inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in BRILINTA therapy [see Clinical Pharmacology (12.3) ].</SentenceText>
<Mention id="M397" type="Trigger" span="50 7" str="monitor"/>
<Mention id="M398" type="Precipitant" span="58 7" str="digoxin" code="N0000005903"/>
<Interaction id="I194" type="Unspecified interaction" trigger="M397" precipitant="M398"/>
</Sentence>
<Sentence id="541" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor .</SentenceText>
<Mention id="M399" type="Trigger" span="36 6;54 8" str="reduce | exposure"/>
<Mention id="M400" type="Precipitant" span="7 14" str="CYP3A inducers" code="n0000190118"/>
<Interaction id="I195" type="Pharmacokinetic interaction" trigger="M399" precipitant="M400" effect="C54356"/>
</Sentence>
<Sentence id="542" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea , bleeding , and other adverse events .</SentenceText>
<Mention id="M401" type="Trigger" span="38 8;58 8" str="increase | exposure"/>
<Mention id="M402" type="Precipitant" span="7 16" str="CYP3A inhibitors" code="N0000191001"/>
<Interaction id="I196" type="Pharmacokinetic interaction" trigger="M401" precipitant="M402" effect="C54355"/>
</Sentence>
<Sentence id="543" LabelDrug="BRILINTA" section="34073-7">
<SentenceText>Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.1 ) .</SentenceText>
<Mention id="M403" type="Trigger" span="60 25" str="reduced the effectiveness"/>
<Mention id="M404" type="Precipitant" span="21 7" str="aspirin" code="N0000006582"/>
<Mention id="M405" type="SpecificInteraction" span="60 37" str="reduced the effectiveness of BRILINTA" code="NO MAP"/>
<Interaction id="I197" type="Pharmacodynamic interaction" trigger="M403" precipitant="M404" effect="M405"/>
</Sentence>
<Sentence id="544" LabelDrug="BRILINTA" section="43685-7">
<SentenceText>Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment , but led to study drug discontinuation in 0.9 % of BRILINTA and 0.1 % of clopidogrel patients in PLATO and 4.3 % of BRILINTA 60 mg and 0.7 % on aspirin alone patients in PEGASUS .</SentenceText>
</Sentence>
<Sentence id="545" LabelDrug="BRILINTA" section="43685-7">
<SentenceText>In PLATO the use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA .</SentenceText>
<Mention id="M406" type="Trigger" span="76 27" str="decreased the effectiveness"/>
<Mention id="M407" type="Precipitant" span="55 7" str="aspirin" code="N0000006582"/>
<Mention id="M408" type="SpecificInteraction" span="76 39" str="decreased the effectiveness of BRILINTA" code="NO MAP"/>
<Interaction id="I198" type="Pharmacodynamic interaction" trigger="M406" precipitant="M407" effect="M408"/>
</Sentence>
<Sentence id="546" LabelDrug="BRILINTA" section="43685-7">
<SentenceText>In the case of intolerable dyspnea requiring discontinuation of BRILINTA , consider prescribing another antiplatelet agent .</SentenceText>
</Sentence>
<Sentence id="547" LabelDrug="BRILINTA" section="43685-7">
<SentenceText>Patients with a history of sick sinus syndrome , 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker were excluded from PLATO and PEGASUS and may be at increased risk of developing bradyarrhythmias with ticagrelor .</SentenceText>
</Sentence>
<Sentence id="548" LabelDrug="BRILINTA" section="43685-7">
<SentenceText>Therefore , after the initial loading dose of aspirin , use BRILINTA with a maintenance dose of aspirin of 75-100 mg see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 ) .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="p2y12 platelet inhibitor" precipitantCode="N0000182142"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lovastatin" precipitantCode="N0000007106" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lovastatin" precipitantCode="N0000007106" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="lovastatin" precipitantCode="N0000007106"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="simvastatin" precipitantCode="N0000005842" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="simvastatin" precipitantCode="N0000005842" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="simvastatin" precipitantCode="N0000005842"/>
<LabelInteraction type="Unspecified interaction" precipitant="digoxin" precipitantCode="N0000005903"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect=" 131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect="267036007: Dyspnea (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyp3a inhibitors" precipitantCode="N0000191001"/>
<LabelInteraction type="Unspecified interaction" precipitant="atazanavir" precipitantCode="N0000022320"/>
<LabelInteraction type="Unspecified interaction" precipitant="clarithromycin" precipitantCode="N0000007316"/>
<LabelInteraction type="Unspecified interaction" precipitant="indinavir" precipitantCode="N0000005722"/>
<LabelInteraction type="Unspecified interaction" precipitant="inhibitors of cyp3a" precipitantCode="N0000191001"/>
<LabelInteraction type="Unspecified interaction" precipitant="itraconazole" precipitantCode="N0000006753"/>
<LabelInteraction type="Unspecified interaction" precipitant="ketoconazole" precipitantCode="N0000007319"/>
<LabelInteraction type="Unspecified interaction" precipitant="nefazodone" precipitantCode="N0000007250"/>
<LabelInteraction type="Unspecified interaction" precipitant="nelfinavir" precipitantCode="N0000006047"/>
<LabelInteraction type="Unspecified interaction" precipitant="ritonavir" precipitantCode="N0000007423"/>
<LabelInteraction type="Unspecified interaction" precipitant="saquinavir" precipitantCode="N0000007376"/>
<LabelInteraction type="Unspecified interaction" precipitant="telithromycin" precipitantCode="N0000010551"/>
<LabelInteraction type="Unspecified interaction" precipitant="voriconazole" precipitantCode="N0000010191"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a inducers" precipitantCode="n0000190118" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyp3a inducers" precipitantCode="n0000190118"/>
<LabelInteraction type="Unspecified interaction" precipitant="carbamazepine" precipitantCode="N0000007470"/>
<LabelInteraction type="Unspecified interaction" precipitant="inducers of cyp3a" precipitantCode="n0000190118"/>
<LabelInteraction type="Unspecified interaction" precipitant="phenobarbital" precipitantCode="N0000005893"/>
<LabelInteraction type="Unspecified interaction" precipitant="phenytoin" precipitantCode="N0000006023"/>
<LabelInteraction type="Unspecified interaction" precipitant="rifampin" precipitantCode="N0000006026"/>

</LabelInteractions></Label>